Selected Publications

Below you will find a selection of publications.


  • Dalmage MR, Nwankwo A, Sur H, Nduom E, Jackson S (2022) A scoping review of pediatric microdialysis: a missed opportunity for microdialysis in the pediatric neuro-oncology setting. Neurooncol Adv, Pubmed ID: 36438644
  • Piotrowski AF, Jackson S (2022)
    Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
    Neuro Oncol, PubMed ID: 35325245
  • Lowden MR, Matthews M, Rivers RC, Hubbard LLN, Boone E, Muhammad T, Billingslea EN, Rohan JP, Simmons J, Jackson S (2022)
    Grassroots efforts to end structural racism throughout the US National Institutes of Health.
    Nat Med, 28:223-224. PubMed ID: 35132268


  • Argersinger DP, Rivas SR, Shah AH, Jackson S, Heiss JD (2021)
    New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma.
    Cancers (Basel), 13 PubMed ID: 34771443
  • Vezina A, Manglani M, Morris D, Foster B, McCord M, Song H, Zhang M, Davis D, Zhang W, Bills J, Nagashima K, Shankarappa P, Kindrick J, Walbridge S, Peer CJ, Figg WD, Gilbert MR, McGavern DB, Muldoon LL, Jackson S (2021) Adenosine A2A receptor activation enhances blood-tumor barrier permeability in a rodent glioma model. Mol Cancer Res, 19(12): 2081-2095. Pubmed ID: 34521765
  • Chukwueke UN, Vera E, Acquaye A, Hervey-Jumper SL, Odia Y, Klesse LJ, Dunbar E, Sharma A, Fonkem E, Thomas AA, Werbowetski-Ogilvie TE, Camelo-Piragua S, Gatson NTN, de la Fuente MI, Armstrong TS, Porter AB, Jackson S (2021)
    SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology.
    Neuro Oncol, 23:1845-1858. PubMed ID: 34302487
  • Martin AM, Jackson S (2021)
    High-risk Medulloblastoma-Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity.
    JAMA Oncol, 7:1322-1323. PubMed ID: 34292302
  • Collins FS, Adams AB, Aklin C, Archer TK, Bernard MA, Boone E, Burklow J, Evans MK, Jackson S, Johnson AC, Lorsch J, Lowden MR, Nápoles AM, Ordóñez AE, Rivers R, Rucker V, Schwetz T, Segre JA, Tabak LA, Hooper MW, Wolinetz C, (2021)
    Affirming NIH's commitment to addressing structural racism in the biomedical research enterprise.
    Cell, 184:3075-3079. PubMed ID: 34115967
  • Otani Y, Sur HP, Rachaiah G, Namagiri S, Chowdhury A, Lewis CT, Shimizu T, Gangaplara A, Wang X, Vézina A, Maric D, Jackson S, Yan Y, Zhengping Z, Ray-Chaudhury A, Kumar S, Ballester LY, Chittiboina P, Yoo JY, Heiss J, Kaur B, Banasavadi-Siddegowda YK (2021)
    Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
    Neuro Oncol, 23:1481-1493. PubMed ID: 33556161


  • Jackson S, Baker EH, Gross AM, Whitcomb P, Baldwin A, Derdak J, Tibery C, Desanto J, Carbonell A, Yohay K, O'Sullivan G, Chen AP, Widemann BC, Dombi E (2020)
    The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.
    Neurooncol Adv, 2:vdaa095. PubMed ID: 32939452


  • Jackson S, Meeks C, Vézina A, Robey RW, Tanner K, Gottesman MM (2019)
    Model systems for studying the blood-brain barrier: Applications and challenges.
    Biomaterials, 214:119217. PubMed ID: 31146177
  • Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, Wu T, Maric D, Chen J, Quezado M, Heiss JD, Gilbert MR, Nduom EK (2019) Cytokine microdialysis for real-time immune monitoring in glioblastoma patients undergoing checkpoint blockade. Neurosurgery, 84(4): 945-953 PubMed ID: 30189044


  • Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA (2018)
    The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.
    Fluids Barriers CNS, 15:2. PubMed ID: 29332604


  • McCord M, Mukouyama YS, Gilbert MR, Jackson S (2017)
    Targeting WNT Signaling for Multifaceted Glioblastoma Therapy.
    Front Cell Neurosci, 11:318. PubMed ID: 29081735
  • Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA (2017)
    The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.
    J Neurooncol, 132:513-519. PubMed ID: 28315063


  • Jackson S, Anders NM, Mangraviti A, Wanjiku TM, Sankey EW, Liu A, Brem H, Tyler B, Rudek MA, Grossman SA (2016)
    The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain.
    J Neurooncol, 126:433-9. PubMed ID: 26626489